Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Michiel S van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T Tagawa, Ulka Vaishampayan, Jeanny B Aragon-Ching, Bernie J Eigl, Rebecca R Hozak, Erik R Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki, Michiel S van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T Tagawa, Ulka Vaishampayan, Jeanny B Aragon-Ching, Bernie J Eigl, Rebecca R Hozak, Erik R Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Abstract
The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC). Here, we use programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) and transcriptome analysis to evaluate the association of immune and angiogenesis pathways, and molecular subtypes, with overall survival (OS) in UC. Higher PD-L1 IHC and immune pathway scores, but not angiogenesis scores, are associated with greater ramucirumab OS benefit. Additionally, Basal subtypes, which have higher PD-L1 IHC and immune/angiogenesis pathway scores, show greater ramucirumab OS benefit compared to Luminal subtypes, which have relatively lower scores. Multivariable analysis suggests patients from East Asia as having lower immune/angiogenesis signature scores, which correlates with decreased ramucirumab OS benefit. Our data highlight the utility of multiple biomarkers including PD-L1, molecular subtype, and immune phenotype in identifying patients with UC who might derive the greatest benefit from treatment with ramucirumab.
Conflict of interest statement
M.S.v.d.H. has received research support from Bristol Myers Squibb, AstraZeneca, Roche, and 4SC; and consultancy fees from BMS, Merck, Sharp & Dhome, Roche, AstraZeneca, Seattle Genetics, Janssen, and Pfizer (all paid to Institute). T.P. reports consulting honoraria from AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche; grants/funding (to Institution) from AstraZeneca, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche; and travel expenses from Roche, Pfizer, MSD, AstraZeneca, and Ipsen. D.P. has received consultancy fees from Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Gilead Sciences, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, and Urogen; grant support from Ada Cap (Advanced Accelerator Applications), Agensys Inc., *Astellas, AstraZeneca, *Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, *Eli Lilly and Company, *Endocyte, Genentech, *Innocrin, MedImmune, Medivation, Merck, Mirati, *Novartis, Pfizer, *Progenics, Replimune, Roche, *Sanofi Aventis, and Seattle Genetics (*denotes study trials have terminated); and ownership interest/investment in Bellicum (sold 7/2020) and Tyme (sold 10/2019). R.d.W. has received consultancy fees from Merck, Sanofi, Astellas, Janssen, Clovis, Orion, and Bayer; speaker fees from Astellas, Sanofi, and Merck; and has received research grants (to Institution) from Sanofi and Bayer. A.N. has a consulting role with Merck, AstraZeneca, Janssen, Incyte, Roche, Rainier Therapeutics, Clovis Oncology, Bayer, Astellas/Seattle Genetics, Ferring, and Immunomedics; has received grant/research support from Merck, Ipsen, and AstraZeneca; and travel expenses/honoraria from Roche, Merck, AstraZeneca, and Janssen. C.N.S. has served in an advisory/consultancy role for Pfizer, MSD, Merck, AstraZeneca, Astellas, Sanofi-Genzyme, Roche-Genentech, Incyte, Medscape, UroToday, and Foundation Medicine. N.M. reports personal fees from Chugai, Janssen, MSD, and Sanofi and grants from Astellas Pharma, Inc., AstraZeneca, Chugai, Eli Lilly and Company, Taiho, Janssen, MSD, Takeda, Amgen, and Pfizer. H.N. reports personal fees from Astellas Pharma, Inc., Chugai, Janssen, Merck, Sharp & Dhome, and Nippon Kayaku and grants from Astellas Pharma, Inc., Ono, and Chugai. S.A.H. has an advisory/consulting role with Roche, MSD, AstraZeneca, BMS, Janssen, Astellas, Bayer, Ipsen, Pfizer, Pierre Fabre, and Sotio and has received research funding from Cancer Research UK, MRC/NIHR, Janssen, and Boehringer Ingelheim. A.B. has an advisory/consulting role with Roche, Pfizer, Bristol Myers Squibb, AstraZeneca, and IPSEN Pharma; receiving honoraria from Bristol Myers Squibb, IPSEN Pharma, and Merck, Sharpe & Dohme and research support from AstraZeneca, Bristol Myers Squibb, Pfizer, IPSEN Steering Committee, and Roche. G.G. has served on an Advisory Board (last 5 years) for Bayer, MSD, Medac, IPSEN Pharma, Merck, LEO Pharma, and Astellas and has acted as an expert for Erbe Elektromedizin, IPSEN Pharma, Roche, Ferring, LEO Pharma, Merck, and Medac. S.T.T. reports research funding (to Institution) from Eli Lilly and Company and Sanofi and honoraria from Sanofi. U.V. reports research support from Astellas, Merck, and Bristol Myers Squibb and consulting and honoraria from AAA Pharmaceutical, Aveo, Bristol Myers Squibb, Bayer, Exelixis, Merck, Pfizer, and Sanofi. J.B.A.-C. serves on the Speakers’ Bureau of Astellas/Seattle Genetics and Bristol Myers Squibb and receives advisory board fees from EMD Serono, Pfizer, Aveo Pharmaceuticals, Immunomedics, AstraZeneca, Exelixis, and Merck. B.J.E. serves in an advisory/consultancy role for Merck, Janssen, AstraZeneca, Roche, Pfizer, EMD Serono, and SEAGEN. R.R.H., E.R.R., M.S.X., and S.W. are employees and shareholders of Eli Lilly and Company. K.M.B.-M. is a shareholder and former employee of Eli Lilly and Company and a shareholder and current employee of AbbVie. A.A. is a shareholder and former employee of Eli Lilly and Company and is currently an employee of Daiichi Sankyo, Inc. (US). A.D. has an advisory/consulting role with AstraZeneca, PACT Pharma, Astellas/Seattle Genetics, Janssen, Nektar, Bristol Myers Squibb, Radmetrix, Merck, Roche/Genentech, Exelixis, and Dyania Health; has received travel reimbursement from Eli Lilly and Company, AstraZeneca, and Seattle Genetics; holds stock and/or other interests in Attica Sciences and ATHOS Therapeutics; and has received research funding (to Institution unless noted otherwise) from AstraZeneca, Genentech/Roche, BMS, Merck Sharp & Dohme, Jounce Therapeutics, Infinity Pharmaceuticals, Seattle Genetics/Astellas, and Kite/Gilead (to A.D.). The disclosures reported herein, for each author, are potential conflicts only on the premise that the companies listed manufacture drugs for cancer treatment. The following authors declare no competing interests: D.C., A.B., J.L.L., R.R.
© 2022. The Author(s).
Figures
References
- Apolo AB, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J. Clin. Oncol. 2017;35:2117–2124.
- Bellmunt J, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017;376:1015–1026.
- Fradet Y, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 2019;30:970–976.
- Powles T, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411.
- Powles T, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2020;383:1218–1230.
- Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
- Sharma P, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–322.
- Iyer G, Rosenberg JE. Novel therapies in urothelial carcinoma: a biomarker-driven approach. Ann. Oncol. 2018;29:2302–2312.
- Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat. Rev. 2020;82:101925.
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322.
- Kamoun A, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 2020;77:420–433.
- Sjodahl G, et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 2012;18:3377–3386.
- Choi W, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165.
- Kardos J, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016;1:e85902.
- Robertson AG, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.
- Seiler R, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 2017;72:544–554.
- Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757.
- Petrylak DP, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390:2266–2277.
- Petrylak DP, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020;21:105–120.
- Agilent Dako. PD-L1 IHC 22C3 pharmDx Interpretation Manual–Urothelial Carcinoma (Agilent Dako, 2018).
- Necchi A, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur. Urol. 2020;77:701–710.
- Zajac M, et al. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagn. Pathol. 2019;14:99.
- McDermott DF, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 2018;24:749–757.
- Motzer RJ, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38:803–817.
- Robinson BD, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 2019;10:2977.
- Loriot Y, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2019;381:338–348.
- Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther. Adv. Med. Oncol. 2017;9:33–45.
- Rosenberg JE, et al. Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance) J. Clin. Oncol. 2021;39:2486–2496.
- Loriot Y, et al. Phase 3 LEAP-011 trial: first-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy [Abstract] Ann. Oncol. 2019;30:v356–v402.
- Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat. Med. 2000;19:2595–2609.
- Agilent Dako. PD-L1 IHC 22C3 pharmDx Interpretation Manual–Non-small Cell Lung Cancer (NSCLC) (Agilent Dako, 2019).
- Roche/Ventana. VENTANA PD-L1 (SP142) Assay—Interpretation Guide for Urothelial Carcinoma (Roche/Ventana, 2016).
- Piccolo SR, et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics. 2012;100:337–344.
- Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425.
- Brauer MJ, et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin. Cancer Res. 2013;19:3681–3692.
- Masiero M, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013;24:229–241.
- Uhlik MT, et al. Stromal-based signatures for the classification of gastric cancer. Cancer Res. 2016;76:2573–2586.
- Ayers M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 2017;127:2930–2940.
- Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
- Kowanetz M, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) Proc. Natl Acad. Sci. USA. 2018;115:E10119–E10126.
- Charoentong P, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
- de Jong JJ, et al. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med. 2019;11:60.
- Damrauer JS, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA. 2014;111:3110–3115.
- Mo Q, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl Cancer Inst. 2018;110:448–459.
- Marzouka NA, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci. Rep. 2018;8:3737.
- Rebouissou S, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med. 2014;6:244ra291.
- Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–2849.
- Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526.
- Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer. 2009;45:228–247.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 1995;57:289–300.
- Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acid Res. 2002;30:207–210.
Source: PubMed